Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients

Review (70 studies; n=17,462) found in studies with follow‐up to 3 years, TOR‐I with antimetabolite (AM) increases risk of graft loss and acute rejection compared with calcineurin inhibitor and AM. TOR‐I with CNI potentially offers alternative to AM with CNI.

Source:

Cochrane Database of Systematic Reviews